Immunotherapy, targeted therapy, and chemotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs, a targeted therapy, and chemotherapy before surgery helps shrink esophageal tumors and improve outcomes. It might make surgery more effective for patients with resectable esophageal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma.
- Your cancer must be in an early but still treatable stage (stage II to IVa) and doctors believe it can be removed with surgery.
- You should not have received any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You should be in generally good health, able to do light activities (like walking) without help, and have adequate organ function.
- You can't have cancer that has spread to other body parts (like the liver or bones).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Hear when a new Esophageal Squamous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.